Miles Andrews

List of Publications by Year in Descending Order

50 papers	4,570 citations	23 h-index	67 g-index
68 ext. papers	6,190 ext. citations	14.7 avg, IF	4.96 L-index

#	Paper	IF	Citations
50	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.. *Science*, **2021**, 374, 1632-1640	33.3	52
49	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in -mutated melanoma. *OncoImmunology*, **2021**, 10, 1992880	7.2	2
48	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. *Nature Medicine*, **2021**, 27, 1432-1441	50.5	57
47	Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. *Nature Communications*, **2020**, 11, 853	17.4	10
46	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. *Nature Communications*, **2020**, 11, 1839	17.4	9
45	A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. *Cancer Reports*, **2019**, 2, e1183	1.5	5
44	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 22699-22709	11.5	119
43	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. *Cell Research*, **2019**, 29, 846-861	24.7	91
42	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncology, The*, **2019**, 20, e378-e389	21.7	88
41	Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors **2019**,		32
40	Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors **2019**,		5
39	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. *Clinical Cancer Research*, **2018**, 24, 3366-3376	12.9	43
38	The good, the (not so) bad and the ugly of immune homeostasis in melanoma. *Immunology and Cell Biology*, **2018**, 96, 497-506	5	3
37	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. *Lancet Oncology, The*, **2018**, 19, 181-193	21.7	168
36	Interaction between Targeted Therapy and Immunotherapy **2018**, 268-285		
35	Predictors of Response to Immune Checkpoint Blockade **2018**, 525-544		
34	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science*, **2018**, 359, 97-103	33.3	1895

33	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. *Frontiers in Immunology*, **2018**, 9, 411	8.4	38
32	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. *Frontiers in Immunology*, **2018**, 9, 946	8.4	13
31	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nature Medicine*, **2018**, 24, 1649-1654	50.5	377
30	Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. *Australasian Journal of Dermatology*, **2017**, 58, e109-e112	1.3	21
29	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. *British Journal of Cancer*, **2017**, 116, 1558-1563	8.7	72
28	Hallmarks of response to immune checkpoint blockade. *British Journal of Cancer*, **2017**, 117, 1-7	8.7	138
27	Reply to XComment on XEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyX *British Journal of Cancer*, **2017**, 116, e15	8.7	1
26	Cancer Evolution during Immunotherapy. *Cell*, **2017**, 171, 740-742	56.2	18
25	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. *EMBO Molecular Medicine*, **2017**, 9, 1011-1029	12	49
24	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. *Cell*, **2017**, 170, 1120-1133.e17	56.2	659
23	PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. *Molecular Cancer*, **2017**, 16, 112	42.1	27
22	Systems analysis identifies miR-29b regulation of invasiveness in melanoma. *Molecular Cancer*, **2016**, 15, 72	42.1	14
21	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. *Annals of Oncology*, **2016**, 27, vi382	10.3	2
20	Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib. *Journal of Clinical Pharmacy and Therapeutics*, **2016**, 41, 354-356	2.2	3
19	Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. *British Journal of Cancer*, **2016**, 114, 1084-9	8.7	90
18	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. *Clinical Cancer Research*, **2015**, 21, 5222-34	12.9	4
17	Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. *Journal of Clinical Pharmacy and Therapeutics*, **2015**, 40, 121-3	2.2	14
16	Patterns of care for metastatic renal cell carcinoma in Australia. *BJU International*, **2015**, 116 Suppl 3, 36-41	5.6	12

15	Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy **2015**, 3, P126		2
14	MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. *Cancer Immunology Research*, **2014**, 2, 351-60	12.5	96
13	The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations. *OncoImmunology*, **2014**, 3, e946367	7.2	8
12	Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. *Frontiers in Oncology*, **2014**, 4, 367	5.3	24
11	Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. *Expert Review of Clinical Immunology*, **2014**, 10, 1107-23	5.1	2
10	Evolving role of tumor antigens for future melanoma therapies. *Future Oncology*, **2014**, 10, 1457-68	3.6	11
9	A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme. *Melanoma Research*, **2014**, 24, 144-9	3.3	6
8	BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. *Journal of Clinical Oncology*, **2013**, 31, e448-51	2.2	47
7	MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells **2013**, 1,		3
6	Human perforin mutations and susceptibility to multiple primary cancers. *OncoImmunology*, **2013**, 2, e24185	7.2	46
5	Antioxidant vitamins and adrenocorticotrophic hormone-induced hypertension in rats. *Clinical and Experimental Hypertension*, **2007**, 29, 465-78	2.2	7
4	Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat. *American Journal of Hypertension*, **2005**, 18, 910-6	2.3	72
3	Nitric oxide donation lowers blood pressure in adrenocorticotrophic hormone-induced hypertensive rats. *Clinical and Experimental Hypertension*, **2004**, 26, 499-509	2.2	9
2	Adrenocorticotropic hormone, blood pressure, and serum erythropoietin concentrations in the rat. *American Journal of Hypertension*, **2004**, 17, 457-61	2.3	8
1	The nitric oxide system in glucocorticoid-induced hypertension. *Journal of Hypertension*, **2002**, 20, 1035-43	3.9	69